Browse
Submit Data
Databases
API
Help

Dataset Information

29 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

JACCRO CC-11 study

ABSTRACT: Interventions: FOLFOXIRI+/-bevacizumab (To 12 courses), 5-FU+Levofolinate+/-bevacizumab (From 13 courses) given on day 1 every 2 weeks, until disease progression or unmanageable toxicity. bevacizumab 5mg/kg/bi-weekly Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): Response Rate Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Colorectal Cancer

PROVIDER: 2613998 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER

Project description:Interventions: FOLFOXIRI+Bevacizumab (until 12 courses) 5-FU+Levofolinate+Bevacizumab (after 13 courses) Bevacizumab 5mg/kg/bi-weekly Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly FOLFOXIRI+Cetuximab (until 12 courses) 5-FU+Levofolinate+etuximab (after 13 courses) Cetuximab (first time) 400 mg/m2/week Cetuximab (after 2nd time) 250 mg/m2/week Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): DpR: Deepness of Response Study Design: Parallel Randomized

| 2633522 | ecrin-mdr-crc

Research on biomarkers in ‘A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors&quot

Project description:Interventions: FOLFOXIRI+/-Bevacizumab (To 12 courses) 5-FU+Levofolinate+/-Bevacizumab (From 13 courses) Bevacizumab 5mg/kg/bi-weekly Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly FOLFOXIRI+/-Cetuximab (To 12 courses) 5-FU+Levofolinate+/-Cetuximab (From 13 courses) Cetuximab (first time) 400 mg/m2/week Cetuximab (after 2nd time) 250 mg/m2/week Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): Correlation between the reported biomarkers or outcome and clinical response. Study Design: Parallel Randomized

| 2633714 | ecrin-mdr-crc

Phase II study of first-line treatment by FOLFOXIRI+bevacizumab in patients with RAS mutant-type metastatic colorectal cancer

Project description:Interventions: FOLFOXIRI +/- bevacizumab (Until 12 course) 5-FU + levoforinate +/- bevacitumab (After 13 course) bevacizumab 5mg/Kg/bi-weekly Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2630485 | ecrin-mdr-crc

Phase I study of 5-FU + Oxaliplatin + Irinotecan + Levofolinate + Panitumumab as the first-line therapy in patients with KRAS or RAS wild-type metastatic colorectal cancer

Project description:Interventions: FOLFOXIRI+Panitumumab (Until 12 courses) Panitumumab 6mg/kg/bi-weekly Irinotecan 165-125mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 3200mg/m2/bi-weekly Primary outcome(s): Recommended Dose Study Design: Single arm Non-randomized

| 2630804 | ecrin-mdr-crc

Phase I study of FOLFOXIRI+cetuximab in patients with RAS wild-type unresectable colorectal cancer

Project description:Interventions: FOLFOXIRI+cetuximab (until 12 courses) Cetuximab 400mg/m2/weekly (initial dose) 250mg/m2/weekly (maintenance) Irinotecan 100-150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): Recommended dose Study Design: Single arm Non-randomized

| 2630948 | ecrin-mdr-crc

Multicenter Phase II Study of FOLFOX/XELOX and Erbitux as First Line Therapy in Patients with Wild Type KRAS/BRAF Metastatic Colorectal Cancer.

Project description:Interventions: Cetuximab 500mg/m2/bi-week(day1) Oxaliplatin 85mg/m2/bi-week(day1) l-LV 200 mg/m2/bi-week(day1) 5-FU/bolus 400mg/m2/bi-week bolus(day1) 5-FU/infusional 2400mg/m2/bi-week(day1-3) Cetuximab 500mg/m2/bi-week(day1) Oxaliplatin 85mg/m2/bi-week(day1) Capecitabine 2000mg/m2/day1-7.bi-wekly Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2618714 | ecrin-mdr-crc

Gunma study - Oxaliplatin-based chemotherapy and Avastin following Irinotecan-based chemotherapy with Erbitux in metastatic colorectal cancer

Project description:Interventions: first line chemotherpy FOLFIRI+Cetuximab (Cetuximab 500mg/m2/bi-week CPT-11 150mg/m2/bi-week l-LV 200mg/m2/bi-week 5-FU/bolus 400mg/m2/bi-week 5-FU/infusional 2,400mg/m2/bi-week (day 1-3)) FOLFIRI+Cetuximab second line chemotherapy (1) mFOLFOX6+Bevacizumab (Bevacizumab 5mg/kg/bi-week L-OHP 85mg/m2/bi-week l-LV 200mg/m2/bi-week 5-FU/bolus 400mg/m2/bi-week 5-FU/infusional 2,400mg/m2/bi-week (day 1-3)) second line chemotherapy (2) XELOX+Bevacizumab (Bevacizumab 7.5mg/kg/tri-week L-OHP 130mg/m2/tri-week Capecitabine 2000mg/m2/day/2 (day 1-15)) Primary outcome(s): Total Progression free survival (PFS1+PFS2): PFS during first-line (PFS1) and PFS during second-line (PFS2) Study Design: Single arm Non-randomized

| 2622536 | ecrin-mdr-crc

Clinical efficacy and safety assessment of high-dose Bevacizumab plus Fluorouracil and Leucovorin (sLV5FU2) in patients with standard chemotherapy refractory metastatic colorectal cancer. phase II multicenter trial.

Project description:Interventions: High-dose Bevacizumab + sLV5FU2 Bevacizumab 10mg/kg (d.i.v) l-LV 200mg/m2 (d.i.v) 5-FU 400mg/m2 (b.i.v) 5-FU 2400mg/m2 (c.i.v) Every 2weeks Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

| 2625196 | ecrin-mdr-crc

A randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancer

Project description:Interventions: arm A-1:mFOLFOX6+Bevacizumab Bevacizumab 5mg/kg/bi-week L-OHP 85mg/m2/bi-week l-LV 200mg/m2/bi-week 5-FU/bolus 400mg/m2/bi-week 5-FU/infusional 2,400mg/m2/bi-week arm A-2: CapeOX+Bevacizumab Bevacizumab 7.5mg/kg/tri-week L-OHP 130mg/m2/tri-week Capecitabine 1200-2100mg/twice/day(day 1-15) arm B-1:TS-1/CPT-11+Bevacizumab(SIRB) Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week arm B-2:TS-1/CPT-11+Bevacizumab(IRIS/BV) Bevacizumab 5mg/kg/(day1and15)/4-weeks CPT-11 100mg/m2/(day1and15)/4-weeks S-1 40-60mg/twice/day(day1-15)/4weeks Primary outcome(s): Progression free survival(PFS) Study Design: Parallel Randomized

| 2623247 | ecrin-mdr-crc

Clinical Efficacy and Safety Assessment of Oxaliplatin and Fluorouraciland, Leucovorin [modified FOLFOX6] in Combination with High-dose Bevacizumab as Second-line Therapy in Patients with Advanced or Recurrent Colorectal Cancer after Failure to Irinotecan. Multicenter Clinical Study.

Project description:Interventions: High-dose Bevacizumab + sLV5FU2 Bevacizumab 10mg/kg (d.i.v) L-OHP 85 mg/m2 (d.i.v) l-LV 200mg/m2 (d.i.v) 5-FU 400mg/m2 (b.i.v) 5-FU 2400mg/m2 (c.i.v) Every 2weeks Primary outcome(s): Progression free survival [PFS] Study Design: Single arm Non-randomized

| 2625142 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data